Swedish biotech rais­es €30M Se­ries A to de­vel­op off-the-shelf gene ther­a­py for sol­id tu­mors

As it ad­vances its in vi­vo cell re­pro­gram­ming plat­form, As­gard Ther­a­peu­tics has raised €30 mil­lion ($32.8 mil­lion) with the help of sev­er­al Big Phar­ma ven­ture arms.

New in­vestors John­son & John­son In­no­va­tion – JJDC and RV In­vest co-led the Se­ries A, with sup­port from ex­ist­ing in­vestors No­vo Hold­ings, Boehringer In­gel­heim Ven­ture Fund and In­dus­tri­fonden. The pro­ceeds will be used to progress As­gard’s lead pro­gram, ex­pand its R&D team and sup­port work on new drug modal­i­ties and de­liv­ery plat­forms, per a Thurs­day re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER